Current medical therapy for inflammatory bowel disease

Southern Medical Journal

Volumn 89, Issue 6, 1996, Pages 556-566

  Bonner, Gregory F ^a  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AMINOSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; BALSALAZIDE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; BUTYRIC ACID; CORTICOSTEROID; CYCLOSPORIN; ENEMA; EUDRAGIT; FLUTICASONE PROPIONATE; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NICOTINE; OLSALAZINE; PREDNISOLONE; PREDNISOLONE 3 SULFOBENZOATE; PREDNISONE; SALAZOSULFAPYRIDINE; SHORT CHAIN FATTY ACID; STEROID; TIXOCORTOL PIVALATE; UNINDEXED DRUG;

BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLON RESECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG METABOLISM; ENTERITIS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUPPOSITORY; TOPICAL DRUG ADMINISTRATION; ULCERATIVE COLITIS;

EID: 0030015060     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007611-199606000-00002     Document Type: Review

References (143)

1. Truelove SC: Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium. BMJ 1958; 2:1072-1077
2. Spencer JA, Kirsner JB: Experience with short and long term courses of local adrenal steroid therapy for ulcerative colitis. Gastroenterology 1962; 42:669-677
3. Danish 5-ASA Group: Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. Dig Dis Sci 1987; 32:598-602
4. Campieri M, Lanfranchi GA, Bazzocchi G, et al: Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 1981; 2:270-271
5. Lima JJ, Giller J, Mackichan JJ, et al: Bioavailability of hydrocortisone retention enemas in normal subjects. Am J Gastroenterol 1980; 73:232-237
6. McIntyre PB, Macrae FA, Berghouse L, et al: Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis. Gut 1985; 26:822-324
7. Lee DAH, Taylor M, James VHT, et al: Rectally administered prednisolone - evidence for a predominantly local action. Gut 1980; 21:215-218
8. Mulder CJJ, Endert E, van der Heide H, et al: Comparison of beclomethasone dipropionate (2 and 3 mg) and prednisolone sodium phosphate enemas (30 mg) in the treatment of ulcerative proctitis. an adrenocortical approach. Neth J Med 1989; 35:18-24
9. Hanauer SB, Kirsner JB, Barrett WE: The treatment of left-sided ulcerative colitis with tixocortol pivalate (Abstract). Gastroenterology 1986; 90:A1449
10. Friedman G: Treatment of refractory proctosigmoiditis and left-sided colitis with a rectally-instilled non-glucocorticoid, non-mineralocorticoid steroid (Abstract). Gastroenterology 1985;88:A1388
11. Karp LC, Targan SR: New enema treatments for inflammatory bowel disease. Dig Dis Sci 1988; 33:85S-87S
12. Danielsson A, Hellers G, Lyrenas E, et al: A controlled randomized trial of budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Scand J Gastroenterol 1987; 22:987-992
13. Lofberg R, Ostergaard-Thomsen O, Langholtz E, et al: Budesonide versus prednisolone enema in active distal ulcerative colitis. a comparative eight week study (Abstract). Gut 1993; 34:41
14. Lamers C, Meiger J, Engels L, et al: Comparative study of the topically acting glucocorticosteroid budesonide and 5-aminosalicylic acid enema therapy of proctitis and proctosigmoiditis (Abstract). Gastroenterology 1991; 100:A223
15. Azad Khan AK, Piris J, Truelove SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; 2:892-895
16. Sutherland LR, Martin F, Greer S, et al: 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92:1894-1898
17. Willoughby CP, Campieri M, Lanfranchi G, et al: 5-Aminosalicylic acid (Pentasa) in enema form for the treatment of active ulcerative colitis. Ital J Gastroenterol 1986; 18:15-17
18. Friedman LS, Richter JM, Kirkham SE, et al: 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial. Am J Gastroenterol 1986; 81:412-418
19. McPhee MS, Swan JT, Biddle WL, et al: Proctocolitis unresponsive to conventional therapy. response to 5-aminosalicylic acid enemas. Dig Dis Sci 1987; 32:76S-81S
20. Guarino J, Chatzinoff M, Berk T, et al: 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: long-term results. Am J Gastroenterol 1987; 82:732-737
21. Biddle WL, Miner PB: Long-term use of mesalamine enemas to induce remission in ulcerative colitis. Gastroenterology 1990; 99:113-118
22. Van Hees PAM, Bakker JH, van Tongeren JHM: Effect of sulphapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis; a study to determine the active moiety of sulphasalazine. Gut 1980; 21:632-635
23. Williams CN: Efficacy and tolerance of 5-aminosalicylic acid suppositories in the treatment of ulcerative proctitis: a review of two double-blind, placebo controlled trials. Can J Gastroenterol 1990; 4:472-475
24. Campieri M, Gionchetti P, Belluzzi A, et al: 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis. J Clin Gastroenterol 1988; 10:406-407
25. m Tc-labeled 5-ASA suppositories. Dig Dis Sci 1987; 32:71S-75S
26. Selby WS, Bennett MK, Jewell DP: Topical treatment of distal ulcerative colitis with 4-aminosalicylic acid enemas. Digestion 1984; 29:231-234
27. Campieri M, Lanfranchi GA, Bertoni F, et al: A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion 1984; 29:204-208
28. Ginsberg AL, Beck LS, McIntosch TM, et al: Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. Ann Intern Med 1988; 108:195-199
29. O'Donnell LJD, Arvind AS, Hoang P, et al: Double blind, controlled trial of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis. Gut 1992; 33:947-949
30. Roediger WE: Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980; 21:793-798
31. Vernia P, Gnaedinger A, Hauck W, et al: Organic anions and the diarrhea of inflammatory bowel disease. Dig Dis Sci 1988; 33:1353-1358
32. Breuer RI, Buto SK, Christ ML, et al: Rectal irrigation with short-chain fatty acids for distal ulcerative colitis. Dig Dis Sci 1991; 36:185-187
33. Breuer RI, Lasher BA, Hinkle MA, et al: Short chain fatty acid therapy in left-sided ulcerative colitis: a randomized clinical trial. Am J Gastroenterol 1991; 85:1351
34. Steinhart AH, Brzezinski A, Baker JP: Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol 1994; 89:179-183
35. Scheppach W, Sommer H, Kirchner T, et al: Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992; 103:51-56
36. Vernia P, Cittadini M, Frieri G, et al: Combined 5-ASA/butyrate treatment in distal ulcerative colitis (Abstract). Gastroenterology 1993; 104:A796
37. Truelove SC, Witts LJ: Cortisone in ulcerative colitis. final report on a therapeutic trial. BMJ 1955; 2:1041-1048
38. Summers RW, Switz DM, Sessions JT, et al: National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77:847-869
39. Malchow H, Ewe K, Brandes JW, et al: European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86:249-266
40. Baron JH, Connell AM, Kanaghinis TG, et al: Out-patient treatment of ulcerative colitis: comparison between three doses of oral prednisone. BMJ 1962; 2:441-446
41. Powell-Tuck J, Brown RL, Chambers TJ, et al: A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission. Digestion 1981; 22:263-270
42. Bello C, Goldstein F, Thornton JT: Alternate-day prednisone treatment and treatment maintenance in Crohn's disease. Am J Gastnenterol 1991; 86:460-466
43. Carpani De Kaski M, Peters M, Lavender JP, et al: Oral fluticasone propionate in active Crohn's disease (Abstract). Gut 1989; 30:A1480
44. Hawthorne AB, Record CO, Holdsworth CD, et al: Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis. Gut 1993; 34:125-128
45. Wright JP, Jarnum S, Schaffalitzky-de Muckadell O: Oral fluticasone propionate compared with prednisolone in treatment of active Crohn's disease (Abstract). Gastroenterology 1993; 104:A803
46. Angus P, Snook JA, Reid M, et al: Oral fluticasone propionate in active distal ulcerative colitis. Gut 1992; 33:711-714
47. Wolman SL, Greenberg GR: Oral budesonide in active Crohn's disease: an initial experience (Abstract). Gastroenterology 1991; 100:A263
48. Lofberg R, Danielsson A, Salde L: Oral budesonide in active Crohn's disease. Aliment Pharmacol Ther 1993; 7:611-616
49. Roth M, Ueberschaer B, Ewe K, et al: Oral slow release budesonide induces remission in active Crohn's disease with little effect on adrenal function (Abstract). Gastroenterology 1992; 102:A688
50. Gross V, Roth M, Uberschaer B: Treatment of active Crohn's ileocolitis with Eudragit coated budesonide (Abstract). Gastroenterology 1994; 106:A710
51. Rutgeerts P, Lofberg R, Malchow H, et al: A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331:842-345
52. Greenberg GR, Feagan BG, Martin F, et al: Oral budesonide for active Crohn's disease. N Engl J Med 1994; 331:836-841
53. Lofberg R, Rutgeerts P, Malchow H, et al: Budesonide CIR for maintenance of remission in ileocecal Crohn's disease. a European multicenter placebo controlled trial for 12 months (Abstract). Gastroenterology 1994; 106:A575
54. Novacek G, Kleinberger M, Vogelsang H, et al: Budesonide in chronic active Crohn's disease (Abstract). Gastroenterology 1994; 106:A709
55. Dick AP, Grayson MJ, Carpenter RG, et al: Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964; 5:437-442
56. Habal FM, Greenberg GR: Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patient with adverse reaction to sulphasalazine. Am J Gastroenterol 1988; 83:15-17
57. Snisky CA, Cort OH, Shanahan F, et al: Oral mesalamine (Asacol) for mild to moderately active ulcerative colitis. Ann Intern Med 1991; 115:350-355
58. Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987; 317:1625-1629
59. Riley SA, Mani V, Goodman MJ, et al: Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988; 29:669-674
60. Dew MJ, Hughes D, Harries AD, et al: Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. BMJ 1982; 285:1012
61. Dew MJ, Harries AD, Evans N, et al: Maintenance of remission in ulcerative colitis with 5-aminosalicylic acid in high dose by mouth. BMJ 1983; 287:23-24
62. Riley SA, Mani V, Goodman MJ, et al: Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulphasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94:1383-1389
63. Tremaine WJ, Schroeder KW, Harrison JW, et al: A randomized, double-blind, placebo-controlled trial of oral 5-ASA (Asacol) in the treatment of symptomatic Crohn's colitis and ileocolitis (Abstract). Gastroenterology 1993; 104:A792
64. Beck IT, Hudacin J, Paterson WG, et al: Mesalazine in the treatment of active Crohn's disease. Can J Gastroenterol 1988; 2(suppl A):63A-70A
65. Prantera C, Pallone F, Brunetti G, et al: Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 1992; 103:363-368
66. Selby WS, Barr GD, Ireland A, et al: Olsalazine in active ulcerative colitis. BMJ 1985; 291:1373-1375
67. Meyers S, Sachar DB, Present DH, et al: Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. Gastroenterology 1987; 93:1255-1262
68. Feurle GE, Theuer D, Velasco S, et al: Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double blind trial. Gut 1989; 30:1354-1361
69. Hetzel DJ, Shearman DJC, Labruoy J, et al: Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scand J Gastroenterol 1988; 23(suppl 148):61-69
70. Rao SSC, Dundas SAC, Holdsworth CD, et al: Olsalazine or sulphasalazine in first attacks of ulcerative colitis? a double-blind study. Gut 1989; 30:675-679
71. Willoughby CP, Cowan RE, Gould SR, et al: Double-blind comparison of olsalazine and sulphasalazine in active ulceralive colitis. Scand J Gastroenterol 1988; 23(suppl 148):40-44
72. Rijk MCM, van Tongeren JHM: The efficacy and safety of sulphasalazine and olsalazine in patients with active ulcerative colitis (Abstract). Gastroenterology 1991; 100:A243
73. Sandberg-Gerzen H, Jarnerot G, Kraaz W: Azodisal sodium in the treatment of ulcerative colitis. Gastroenterology 1986; 90:1024-1030
74. Ireland A, Mason CH, Jewell DP: Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 1988; 29:835-837
75. Rijk MCM, van Lier HJJ, van Tongeren JHM: Relapse-preventing effect and safety of sulphasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. Am J Gastroenterol 1992; 87:438-442
76. Kiilerich S, Ladefoged K, Rannem T: Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Gut 1992; 33:252-255
77. Kruis W, Judmaier G, Kayasseh L, et al: Double-blind dose-finding study for olsalazine vs. sulfasalazine for maintenance therapy for ulcerative colitis (Abstract). Gastroenterology 1992; 102:A649
78. Rasmussen SN, Bondesen S, Hvidberg EF, et al: 5-Aminosalicylic acid in a slow-release preparation: bioavailability, plasma levels, and excretion in humans. Gastroenterology 1982; 83:1062-1070
79. Hanauer S, Beshears L, Wilkinson G, et al: Induction of remission in a dose-ranging study of oral mesalamine capsules (Pentasa) (Abstract). Gastroenterology 1990; 98:A174
80. Miner P, Nostrant T, Wruble L, et al: Multicenter trial of Pentasa for active ulcerative colitis (Abstract). Gastroenterology 1991; 100:A231
81. Miner P, Schwartz J, Aora S, et al: Maintenance of remission in ulcerative colitis (UC) patients with controlled-release mesalamine capsules (Pentasa) (Abstract). Gastroenterology 1992; 102:A666
82. Mulder CJJ, Tytgat GN, Weterman IT, et al: Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 1988; 95:1449-1453
83. Singleton JW, Hanauer SB, Gitnick GL, et al: Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 1993; 104:1293-1301
84. Rasmussen SN, Lauritsen K, Tage-Jensen U, et al: 5-Aminosalicylic acid in the treatment of Crohn's disease. Scand J Gastroenterol 1987: 22:877-883
85. Mahida YR, Jewell DJ: Slow-release 5-aminosalicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 1990; 45:88-92
86. Gendre JP, Mary JY, Florent C, et al: Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. Gastroenterology 1993; 104:435-439
87. Brignola C, Iannone P, Pasquali S, et al: Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci 1992; 37:29-32
88. Rachmilewitz D, International Study Group: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. BMJ 1989; 298:82-86
89. Rutgeert P, International Study Group: Comparative efficacy of coated oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1989; 3:183-191
90. Nester T, Borgen L, Rowasa Study Group: A double-blind comparison of controlled release mesalamine tablets and sulphasalazine (SAS) in the treatment of ulcerative colitis (Abstract). Gastroenterology 1992; 102:A630
91. Martin R, Sutherland L, Beck IT, et al: Comparative efficacy and safety of oral mesalamine (Salofalk) versus prednisone in the short-term treatment of active Crohn's disease. a Canadian multicentre controlled trial. Can J Gastroenterol 1990; 4:452-457
92. International Mesalazine Study Group: Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther 1990; 4:55-64
93. Bresci G, Petrucci A, Banti S: 5-Aminosalicylic acid in the prevention of relapses of Crohn's disease in remission: a long-term study: Int J Clin Pharmacol Res 1991; 11:200-202
94. Messori A, Brignola C, Trallori G, et al: Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994; 89:692-698
95. Jewell DP, Truelove SC: Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. BMJ 1974; 4:627-630
96. Kirk AP, Lennard-Jones JE: Controlled trial of azathioprine in chronic ulcerative colitis. BMJ 1982; 284:1291-1292
97. Rosenberg JL, Wall AJ, Levin B, et al: A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69:96-99
98. Hawthorne AB, Logan RFA, Hawkey CJ, et al: Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305:20-22
99. Rhodes J, Bainton D, Beck P, et al: Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2:1273-1276
100. Klein M, Binder HJ, Mitchell M, et al: Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974; 66:916-922
101. Rosenberg JL, Levin B, Wall AJ, et al: A controlled trial of azathioprine in Crohn's disease. Dig Dis 1975; 20:721-726
102. Ewe K, Press AG, Singe CC, et al: Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993; 105:367-372
103. Present DH, Korelitz BI, Wisch N, et al: Treatment of Crohn's disease with 6-mercaptopurine. N Engl J Med 1980; 302:981-987
104. O'Brien JJ, Bayless TM, Bayless JA: Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991; 101:39-46
105. Nyman M, Hansson I, Eriksson S: Long-term immunosuppressive treatment in Crohn's disease. Scand J Gastroenterol 1985; 20:1197-1203
106. Perrault J, Greseth JLM, Tremaine WJ: 6-Mercaptopurine therapy in selected cases of corticosteroid-dependent Crohn's disease. Mayo Clin Proc 1991; 66:480-484
107. Willoughby JMT, Kumar PJ, Beckett J, et al: Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2:944-947
108. O'Donoghue DP, Dawson AM, Powell-Tuck J, et al: Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 2:955-957
109. Present DH, Meltzer SJ, Krumholz MP, et al: 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111:641-649
110. Lichtiger S, Present DH, Kornbluth A, et al: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841-1845
111. Lichtiger S, Present DH: Preliminary report: cyclosporine in treatment of severe active ulcerative colitis. Lancet 1990; 336:16-19
112. Sandborn WJ, Goldman DH, Lawson GM, et al: Measurement of colonic tissue cyclosporine concentration in children with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1992; 15:125-129
113. Hyams JS, Treem WR: Cyclosporine treatment of fulminant colitis. J Pediatr Gastroenterol Nutr 1989; 9:383-387
114. Kirschner BS, Whitington PF, Black DD, et al: Cyclosporine-induced remission in severe colitis unresponsive to corticosteroid therapy (Abstract). Pediatr Res 1987; 21:271A
115. Stange EF, Fleig WE, Rehklau E, et al: Cyclosporine A treatment in inflammatory bowel disease. Dig Dis Sci 1989; 34:1387-1392
116. Tsadok JM, O'Brien JJ: Intravenous cyclosporine (CYA) in the therapy of severe active ulcerative colitis (Abstract). Gastroenterology 1994; 106:A707
117. Treem WR, Davis PM, Hyams JS: Cyclosporine treatment of severe ulcerative colitis in children. J Pediatr 1991; 119:994-997
118. Actis GC, Ottobrelli A, Lagget M, et al: Intravenous cyclosporine (CY-A) for refractory ulcerative colitis (UC). a phase II study to reduce dose and toxicity (Abstract). Gastroenterology 1994; 106:A707
119. Baert F, Hanauer S: CYA in severe steroid-resistant UC: long-term results of therapy (Abstract). Gastroenterology 1994; 106:A553
120. Kozarek R, Bedard G, Patterson D, et al: Cyclosporine (Cy) use in the pre-colectomy chronic ulcerative colitis (CUC) patient in the Pacific Northwest (Abstract). Gastroenterology 1994; 106:A707
121. Kornbluth A, Lichtiger S, Present D, et al: Long-term results of oral cyclosporine in patients with severe ulcerative colitis: a double-blind, randomized, multi-center trial (Abstract). Gastroenterology 1994; 106:A708
122. Brynskov J, Freund L, Rasmussen SN, et al: A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 321:845-850
123. Brynskov J, Freund L, Rasmussen SN, et al: Final report on a placebo-controlled, double-blind, randomized, multicenter trial of cyclosporine treatment in active chronic Crohn's disease. Scand J Gastroenterol 1991; 26:689-695
124. Feagan BG, McDonald JWD, Rochon J, et al: Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994; 330:1846-1851
125. Sandborn WJ, Tremaine WJ: Cyclosporine treatment in inflammatory bowel disease. Mayo Clin Proc 1992; 67:981-990
126. Hanauer SB, Smith MB: Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporine A. Am J Gastroenterol 1993; 88:646-649
127. Lichtiger S: Cyclosporine therapy in inflammatory bowel disease: open-label experience. Mt Sinai J Med 1990; 57:315-319
128. Kozarek RA, Patterson DJ, Gelfand MD, et al: Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110:353-356
129. Baron TH, Truss CD, Elson CO: Steroid sparing effect of oral methotrexate in refractory inflammatory bowel disease (Abstract). Gastroenterology 1991; 100:A195
130. Kozarek RA, Patterson DJ, Botoman VA, et al: Methotrexate use in inflammatory bowel disease patients who have failed azathioprine or 6-mercaptopurine (Abstract). Gastroenterology 1991; 100:A222
131. Chamiot-Prieur C, Lemann M, Mesnard B, et al: Treatment of refractory Crohn's disease with methotrexate (Abstract). Gastroenterology 1993; 104:A680
132. Feagan BG, Rochon J, Fedorak RN, et al: Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332:292-297
133. Srivastava ED, Russell MAH, Feyerabend C, et al: Transdermal nicotine in active ulcerative colitis. Eur J Gastroenterol 1991; 3:815-818
134. Lashner BA, Hanauer SB, Silverstein MD: Testing nicotine gum for ulcerative colitis patients. Dig Dis Sci 1990; 35:827-832
135. Pullan RD, Rhodes J, Ganesh S, et al: Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994; 330:811-815
136. Thomas GAO, Rhodes J, Mani V, et al: Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 1995; 332:988-992
137. Gitnick G: Antibiotics and inflammatory bowel diseases. Gastroenterol Clin North Am 1989; 18:51-56
138. Bernstein LH, Frank MS, Brandt LJ, et al: Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980; 79:357-365
139. Brandt LJ, Bernstein LH, Boley SJ, et al: Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982; 83:383-387
140. Jakobovits J, Schuster MM: Metronidazole therapy for Crohn's disease and associated fistulae. Am J Gastroenterol 1984; 79:533-540
141. Blichfeldt P, Blomhoff JP, Myhre E, et al: Metronidazole in Crohn's disease. a double-blind crossover clinical trial. Scand J Gastroenterol 1978; 13:123-127
142. Ursing B, Alm T, Barany F, et al: A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. Gastroenterology 1982; 83:550-562
143. Sutherland L, Singleton J, Sessions J, et al: Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32:1071-1075